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Objective: To investigate the risk of hospitalization and death following prostate biopsy.
Study design: Retrospective cohort study.
Methods: Our study population comprised 10,285 patients with a record of first ever prostate
biopsy between 2009 and 2013 on computerized acute hospital discharge or outpatient
records covering Scotland. Using the general population as a comparison group, expected
numbers of admissions/deaths were derived by applying age-, sex-, deprivation category-,
and calendar year-specific rates of hospital admissions/deaths to the study population.
Indirectly standardized hospital admission ratios (SHRs) and mortality ratios (SMRs) were
calculated by dividing the observed numbers of admissions/deaths by expected numbers.
Results: Compared with background rates, patients were more likely to be admitted to
hospital within 30 days (SHR 2.7; 95% confidence interval 2.4, 2.9) and 120 days (SHR 4.0; 3.8,
4.1) of biopsy. Patients with prior co-morbidity had higher SHRs. The risk of death within 30
days of biopsy was not increased significantly (SMR 1.6; 0.9, 2.7), but within 120 days, the
risk of death was significantly higher than expected (SMR 1.9; 1.5, 2.4). The risk of death
increased with age and tended to be higher among patients with prior co-morbidity.
Overall risks of hospitalization and of death up to 120 days were increased both in men
diagnosed and those not diagnosed with prostate cancer.
Conclusions: Higher rates of adverse events in older patients and patients with prior co-
morbidity emphasizes the need for careful patient selection for prostate biopsy and jus-
tifies ongoing efforts to minimize the risk of complications.
© 2016 The Authors. Published by Elsevier Ltd on behalf of The Royal Society for Public
Health. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).lligence, NHS National S
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Screening for prostate cancer using the prostate-specific
antigen (PSA) test remains controversial. In a Cochrane re-
view, based on a meta-analysis of five randomized trials, the
authors concluded that screening does not reduce prostate
cancer-specific and overall mortality; that harms associated
with PSA-based screening and subsequent diagnostic eval-
uations are frequent, and moderate in severity; and that
over-diagnosis and over-treatment are common and are
associated with treatment-related harms.1
Limited information is published on the potential
adverse consequences of prostate screening in real world
clinical practice compared with appropriate control pop-
ulations. The aim of this study was to investigate the risk of
hospitalization and death following prostate biopsy in a
cohort of patients selected from computerized hospital re-
cords in Scotland.Methods
We performed a retrospective cohort study relating first ever
prostate biopsy to hospitalization and/or death within 30 and
120 days. Record linkage was achieved using the Community
Health Index number, a unique identifying number used by
the National Health Service (NHS) in Scotland. We studied the
first biopsy in any individual because the inclusion of every
biopsy would result in a complex analysis, and the decision to
undertake a subsequent biopsy may be influenced by com-
plications arising after a previous biopsy.
The study population comprised patients with a record of
first ever prostate biopsy between 2009 and 2013 inclusive on
computerized acute hospital discharge or outpatient records
covering the whole of Scotland (total population approxi-
mately 5.3 million). Patients were selected on the basis of
procedure codes drawn from the fourth revision of the Office
of Population Censuses and Surveys Classification of Surgical
Operations and Procedures (OPCS-4)2 (See Appendix). Endo-
scopic biopsies of prostate and open biopsies of prostate were
not included. Diagnosis of prostate cancer within 120 days
before or after prostate biopsy was established from linked
Scottish Cancer Registry records.
Socio-economic position is likely to be an important con-
founding factor because men from less deprived areas of
residence are more likely to have a PSA test,3 but less likely to
die from all causes combined. Therefore, the Scottish Index of
Multiple Deprivation 2012 was used as a postcode-referenced,
small area indicator of socio-economic position.4 This has
seven domains (income, employment, education, housing,
health, crime, and geographical access) at 'datazone' level
(areas with approximately 500e1000 household residents),
which have been combined into an overall index to identify
area concentrations of multiple deprivation.
In the context of this study, we sought to assess data
quality in two ways. First, for a single region of Scotland
(Tayside, total population approximately 414,000), we linked
electronic pathology records for prostate biopsy to prostate
biopsies on acute hospital discharge and outpatient recordsfor the period 2009e2013. For this part of the study, we did
not restrict the analysis to first biopsies. We determined the
proportion of prostate biopsies that were unrecorded on
hospital records and, of greater concern, the proportion of
prostate biopsies recorded in error on hospital records. Sec-
ond, for all Scottish patients identified as dying within 30
days of prostate biopsy, we reviewed their archived primary
care records (or when these were inadequate, their electronic
pathology record) to verify whether they had indeed under-
gone prostate biopsy within 30 days of death.
For the whole of Scotland, the numbers of prostate bi-
opsies were examined in conjunction with numbers of ad-
missions to hospital (continuous inpatient stays) and
numbers of deaths, both within 30 and 120 days. Crude rates
of hospitalization and death per 1000 patients were calcu-
lated for all patients combined, and also stratified by age
group, deprivation fifth, prior co-morbidity, and whether
diagnosed with prostate cancer. Reasons for admission to
hospital were summarized for all patients combined,
and separately for patients diagnosed or not diagnosed
with prostate cancer. In particular, we focused on any
mention of haemorrhage (e.g. haematuria), infection (e.g.
urinary ± bacteraemia, rectal abscess), other urinary symp-
toms (e.g. retention, incontinence) and any mention of
invasive procedures (e.g. catheterization). See Appendix for a
detailed list of potentially relevant diagnostic (ICD-10) and
procedure (OPCS-4) codes. Two indicators of prior co-
morbidity, derived from hospital discharge data, were used:
Charlson score based on primary diagnosis,5 and prior
inpatient bed days, both during the five year period imme-
diately before prostate biopsy (but in the case of bed days,
excluding the most recent six-month period, which would
seem more likely to include some prostate-associated
morbidity).
Indirectly standardized hospital admission ratios (SHRs)
and mortality ratios (SMRs) were calculated by dividing the
observed numbers of admissions/deaths by expected
numbers. Again, results were stratified by subgroups, as
described above. Both age and co-morbidity have been shown
to predict the risk of mortality independently following
prostate biopsy in previous research.6 Follow-up was from
date of prostate biopsy to 30/120 days after biopsy, or to date
of death, whichever occurred first. For the hospitalization
analysis, all continuous inpatient stays were counted. Using
the general population as a comparison group, expected
numbers of admissions/deaths were derived by applying age-,
sex-, deprivation category-, and calendar year-specific rates of
hospital admissions/deaths to the study population. Rates
were calculated using population data sourced from National
Records of Scotland. The 95% confidence intervals (CIs)
around SHRs and SMRs were calculated based on the
assumption that the observed numbers of admissions/deaths
followed a Poisson distribution. SHRs and SMRs with 95% CI
that do not include the value 1.0 were regarded as statistically
significant.
Finally, for patients who died within 30 days of a prostate
biopsy, their original death certificates were reviewed, taking
account of the interval between biopsy and death, and the
diagnoses listed, to assess whether the prostate biopsy might
have contributed to their death.
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Data quality and representativeness
Data supplied by Tayside pathology laboratory included 1681
records of prostate biopsy. Computerized hospitalization
data yielded only 508 records of prostate biopsy for patients
treated in Tayside hospitals during the same period
(2009e2013). Of these 508 records, 495 (97%) had a record of
prostate biopsy within seven days of the corresponding pa-
thology record, and 477 (94%) matched exactly for date of
biopsy. Assuming pathology records to be the 'gold standard',
and based on exact matching of dates, the sensitivity for
detecting prostate biopsy using hospitalization records was
only 28% (477/1681). Hospitalization records included a
slightly higher proportion of patients aged 80 years (11% vs
7%; Chi-squared ¼ 8.0; P ¼ 0.046) but did not differ in terms of
the distribution of deprivation categories (Chi-squared ¼ 3.6;
P ¼ 0.47).
Across the whole of Scotland, we were able to verify that
all 14 patients dying within 30 days of prostate biopsy (ac-
cording to linked hospitalization and mortality records),
had indeed undergone prostate biopsy 30 days before
death.Table 1 e Characteristics of the study population.
Characteristic Patients Admiss
No. % 30 day
No.
All patients combined 10,825 100.0 492
Age group (years)
<50 218 2.0 9
50e59 1948 18.0 88
60e69 4973 45.9 201
70e79 3297 30.5 175
80 389 3.6 19
SIMD fifth
1 e Most deprived 1770 16.4 103
2 1797 16.6 79
3 1989 18.4 80
4 2382 22.0 112
5 e Least deprived 2887 26.7 118
Prior co-morbidity (Charlson score)
0 conditions 7058 65.2 290
1e2 conditions 3754 34.7 202
3 conditions 13 0.1 0
Prior co-morbidity (bed days)c
0 7058 65.2 290
1e10 3767 34.8 202
11 0 0.0 0
Diagnosed with prostate cancerd
Yes 5227 48.3 218
No 5598 51.7 274
a Continuous inpatient stays.
b Rate per 1000 during 30 or 120 days, respectively.
c Number of inpatient bed days in the five years (excluding the most rec
d Within 120 days, before or after prostate biopsy date.Main results
The main study population included 10,285 patients under-
going first ever prostate biopsy (Table 1). At the time of their
biopsy, the majority (80%) were aged 60 years, and 34% were
aged 70 years. A higher percentage (27%) was from the least
deprived compared with the most deprived (16%) areas of
residence. The majority of patients (65%) had no recorded
prior co-morbidity, and almost half (48%) were diagnosedwith
prostate cancer within 120 days of their biopsy. Although
there is no clear pattern by age and deprivation, admission
rates were higher in patients with prior co-morbidity, whereas
mortality rates increased with age and prior co-morbidity.
Although not shown in Table 1, the mortality rate within 120
days for patients aged <60 years was 2.8 per 1000.
The most common reason for hospital admission poten-
tially associated with prostate biopsy was 'other urinary
symptoms', although most admissions were not obviously
associated with prostate biopsy, especially within 120 days of
the procedure (Table 2). Compared to patients diagnosed with
prostate cancer, patients not diagnosed had a higher per-
centage of potentially relevant complications recorded on
their hospital admission records.
Compared with background rates, following prostate bi-
opsy, patients were 2.7 times and 4.0 times more likely to beionsa within Deaths within
s 120 days 30 days 120 days
Rateb No. Rateb No. Rateb No. Rateb
45.5 2929 270.6 14 1.3 67 6.2
41.3 49 224.8 0 0.0 0 0.0
45.2 593 304.4 0 0.0 6 3.1
40.4 1361 273.7 3 0.6 24 4.8
53.1 837 253.9 8 2.4 25 7.6
48.8 89 228.8 3 7.7 12 30.8
58.2 510 288.1 3 1.7 13 7.3
44.0 481 267.7 2 1.1 10 5.6
40.2 545 274.0 4 2.0 15 7.5
47.0 674 283.0 4 1.7 16 6.7
40.9 719 249.0 1 0.3 13 4.5
41.1 1544 218.8 8 1.1 29 4.1
53.8 1380 367.6 6 1.6 38 10.1
0.0 5 384.6 0 0.0 0 0.0
41.1 1544 218.8 8 1.1 29 4.0
53.6 1385 367.7 6 1.6 38 10.1
0.0 0 0.0 0 0.0 0 0.0
41.7 1816 347.4 7 1.2 35 6.7
48.9 1113 198.8 7 1.4 32 5.7
ent six months) before prostate biopsy.
Table 2 e Numbers and percentages of patients admitted to hospital within 30 and 120 days, by reason for admission.
Reason for admission Admissions within 30 days Admissions within 120 days
No. % No. %
All patients combined
Haemorrhagea 14 2.8 62 2.1
Infectiona 19 3.9 102 3.5
Other procedure-related complicationsa 0 0.0 2 0.1
Other urinary symptomsa 81 16.5 366 12.5
Multiple complicationsb 24 4.9 45 1.5
Other reasons 354 72.0 2352 80.3
Totalc 492 100 2929 100
Patients diagnosed with prostate cancerd
Haemorrhagea 4 1.8 22 1.2
Infectiona 6 2.8 39 2.1
Other procedure-related complicationsa 0 0.0 1 0.1
Other urinary symptomsa 31 14.2 236 13.0
Multiple complicationsb 6 2.8 18 1.0
Other reasons 171 78.4 1500 82.6
Totalc 218 100 1816 100
Patients not diagnosed with prostate cancerd
Haemorrhagea 10 3.6 40 3.6
Infectiona 13 4.7 63 5.7
Other procedure-related complicationsa 0 0.0 1 0.1
Other urinary symptomsa 50 18.2 130 11.7
Multiple complicationsb 18 6.6 27 2.4
Other reasons 183 66.8 852 76.5
Totalc 274 100 1113 100
a Based on any mention of relevant ICD-10/OPCS-4 codes (See Appendix).
b Patients who fall into more than one of the preceding four categories.
c Total continuous inpatient stays.
d Within 120 days, before or after prostate biopsy date.
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(Table 3). There were no consistent patterns by age or depri-
vation, but patients with prior co-morbidity had higher SHRs.
The risk of admission within 30 days was higher among pa-
tients not diagnosed with prostate cancer within 120 days of
their biopsy compared with those diagnosed. However, this
pattern was reversed with respect to admissions within 120
days of biopsy.
For all patients combined, the SMR within 30 days of pros-
tate biopsy was increasedmodestly (SMR ¼ 1.6) but the 95% CI
includes the value 1.00, implying no statistically significant
difference frombackgroundmortality rates (Table4).However,
within 120 days of biopsy, the risk of death was significantly
higher than expected (SMR ¼ 1.9; 95% CI 1.5, 2.4). No deaths
occurred in the under 50 years age group within 120 days of
biopsy, and only six occurred in the 50e59 years age group
(Table 1). Although not shown in Table 4, the SMR within 120
days of biopsy for patients aged <60 years was 0.9 (95% CI 0.3,
1.9).The relative riskofdeathotherwise increasedwithageand
tended to be higher among patients with prior co-morbidity.
There was no obvious pattern by deprivation category. The
risk of death within 120 days of biopsy was increased both in
patients diagnosed (SMR ¼ 2.1; 95% CI 1.4, 2.9) and not diag-
nosed (SMR ¼ 1.8; 95% CI 1.2, 2.5) with prostate cancer.Review of death certificates
We attempted to classify deaths within 30 days of biopsy as
‘probably related’, ‘probably unrelated’ or ‘uncertain’. Fourcases were classified as uncertain, and the remaining 10 cases
as probably unrelated.Discussion
In a large population of hospital patients undergoing first ever
prostate biopsy, we found higher than expected risks of
admission to hospital within 30 and 120 days of the procedure.
The majority of admissions were for reasons not obviously
associated with prior biopsy, and some admissions weremost
likely associated with the diagnosis of prostate cancer. How-
ever, the risk of hospital admission was increased both in
patients with and without prostate cancer. Moreover, it is not
appropriate to downplay complications arising in patients
with prostate cancer since a proportion of these are likely to
represent over-diagnosed cases.7 It is also possible that some
admissions for other reasons, such as cardiovascular disease,
could be related to prostate biopsy.
There was no statistically significant evidence of an
increased risk of dying within 30 days of a prostate biopsy,
although it was not possible to estimate 30-day mortality
precisely due to limited statistical power (14 deaths).
Although the overall risk of death was almost doubled
(SMR ¼ 1.9) within 120 days of biopsy, and notwithstanding
the challenges in determining and recording the true under-
lying cause of death,8e10 more than a quarter of the deaths
(18/67) were attributed to prostate cancer. However, as with
hospital admission, the risk of death up to 120 days was
Table 3 e Standardized hospital admission ratios (SHR) with 95% confidence intervals (CIs) by patient characteristics.
Characteristic Admissionsa within 30 days Admissionsa within 120 days
SHR 95% CI SHR 95% CI
LCL UCL LCL UCL
All patients combined 2.7 2.4 2.9 4.0 3.8 4.1
Age group (years)
<50 2.4 1.1 4.5 3.2 2.4 4.2
50e59 2.6 2.1 3.2 4.4 4.1 4.8
60e69 2.4 2.1 2.7 4.0 3.8 4.3
70e79 3.1 2.6 3.6 3.7 3.5 4.0
80 2.9 1.7 4.5 3.4 2.8 4.2
SIMD fifth
1 e Most deprived 2.6 2.1 3.2 3.3 3.0 3.5
2 2.3 1.8 2.9 3.5 3.2 3.8
3 2.4 1.9 3.0 4.1 3.7 4.4
4 3.0 2.5 3.7 4.6 4.3 5.0
5 e Least deprived 2.9 2.4 3.4 4.4 4.1 4.7
Prior co-morbidity (Charlson score)
0 conditions 2.4 2.1 2.7 3.2 3.1 3.4
1e2 conditions 3.1 2.7 3.6 5.4 5.1 5.6
3 conditions 0.0 NA NA 5.1 1.7 12.0
Prior co-morbidity (bed days)b
0 2.4 2.1 2.7 3.2 3.1 3.4
1e10 3.1 2.7 3.6 5.4 5.1 5.6
11 0.0 NA NA 0.0 NA NA
Diagnosed with prostate cancerc
Yes 2.4 2.1 2.8 5.1 4.9 5.3
No 2.9 2.5 3.2 2.9 2.7 3.1
LCL, lower confidence limit; UCL, upper confidence limit; NA, not applicable.
SIMD, Scottish Index of Multiple Deprivation.
a Continuous inpatient stays.
b Number of inpatient bed days in the five years (excluding the most recent six months) before prostate biopsy.
c Within 120 days, before or after prostate biopsy date.
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The risk of death was higher in older patients and those with
prior co-morbidity, consistent with the findings of Gallina
et al.6 Although the mortality rate within 120 days of prostate
biopsy for patients aged less than 60 years was slightly higher
than that reported by Gallina et al. (2.8 compared with 2.0 per
1000)6 and exceeds the threshold beyond which any years of
life gained through PSA screening would be outweighed by
years of life lost,11 the calculation is based on a small number
of events (six deaths) and corresponds to a SMR of 0.9 (95% CI
0.3, 1.9) implying no excess mortality risk in this age group. It
is certainly possible that some or all of the deaths were not
associated with prostate biopsy. Perhaps it is also worth
noting that there was no evidence of excess mortality asso-
ciated with prostate biopsy in either the ERSPC12 or the
PLCO13 screening trials. However, it is also important to note
that participants in trials of prostate cancer screening are
likely to be asymptomatic and healthy. In contrast, in the
absence of an organized prostate cancer screening pro-
gramme in Scotland, our study population is likely to include
a high proportion of men presenting with relevant
symptoms.
Comparison with other observational studies is also chal-
lenging because of differences in profiles of study populations
and control populations. Selection of an appropriate control
population for men undergoing prostate biopsy is notstraightforward. For example, Loeb et al.14 found that biopsied
men were at substantially decreased risk of death within 30
days compared with their control population (adjusted OR
0.29; 95% CI 0.22, 0.38). It seems implausible that prostate bi-
opsy could reduce a man's risk of dying from all causes. The
most likely explanation is that men selected for prostate bi-
opsy tend to be healthier, on average. For the analyses re-
ported in Tables 3 and 4, we used the general background
population as our control population. It could be argued that
this approach has led to an over-estimation of risks of com-
plications on the grounds that men being investigated for
possible prostate cancermight be expected to be at higher risk
of hospitalization and death. However, as noted above, higher
risks of hospitalization and death were also seen in men who
were not diagnosed with prostate cancer.
As with mortality data, it can sometimes be difficult to be
certain that hospital admissions are directly or indirectly
associated with prior prostate biopsy. Nevertheless, many
studies suggest that prostate biopsy can be associated with a
range of subsequent morbidity, especially infection.3,13,15e18
The fact that 34% of prostate biopsies were carried out in
men aged 70 years, coupled with higher rates of adverse
events in older patients and patients with prior co-morbidity,
raises the possibility that there may be scope to improve
selection of patients for prostate biopsy. Even in the USA,
where rates of PSA testing have been comparatively high
Table 4 e Standardized mortality ratios (SMR) with 95% confidence intervals (CIs) by patient characteristics.
Characteristic Deaths within 30 days Deaths within 120 days
SMR 95% CI SMR 95% CI
LCL UCL LCL UCL
All patients combined 1.6 0.9 2.7 1.9 1.5 2.4
Age group (years)
<50 0.0 NA NA 0.0 NA NA
50e59 0.0 NA NA 1.0 0.3 2.1
60e69 0.8 0.2 2.2 1.5 1.0 2.3
70e79 3.0 1.3 5.9 2.3 1.5 3.5
80 9.8 2.0 28.6 9.9 5.1 17.3
SIMD fifth
1 e Most deprived 1.6 0.3 4.7 1.8 0.9 3.0
2 1.2 0.1 4.2 1.5 0.7 2.7
3 2.4 0.7 6.3 2.3 1.3 3.8
4 2.3 0.6 5.8 2.3 1.3 3.7
5 e Least deprived 0.6 0.0 3.2 1.9 1.0 3.2
Prior co-morbidity (Charlson score)
0 conditions 1.4 0.6 2.8 1.3 0.9 1.8
1e2 conditions 2.0 0.7 4.3 3.1 2.2 4.3
3 conditions 0.0 NA NA 0.0 NA NA
Prior co-morbidity (bed days)a
0 1.4 0.6 2.8 1.3 0.9 1.8
1e10 2.0 0.7 4.3 3.1 2.2 4.3
11 0.0 NA NA 0.0 NA NA
Diagnosed with prostate cancerb
Yes 1.7 0.7 3.4 2.1 1.4 2.9
No 1.6 0.6 3.2 1.8 1.2 2.5
LCL, lower confidence limit; UCL, upper confidence limit; NA, not applicable.
a Number of inpatient bed days in the five years (excluding the most recent six months) before prostate biopsy.
b Within 120 days, before or after prostate biopsy date.
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not recommend routine PSA screening inmen aged >70 years
or in any man with less than a 10e15 year life expectancy.20
A strength of our study is that we were able to include
some assessment of data quality. Our comparison with pa-
thology records for one region of Scotland suggests that
hospitalization data may exclude a high proportion of pros-
tate biopsies. If outpatient biopsies are more likely to be
performed on men at lower risk of complications, and less
likely to be recorded in hospitalization data, our study may
have over-estimated rates of complications. Hospitalization
records included a slightly higher proportion of patients aged
80 years (11% vs 7%), but this seems unlikely to have dis-
torted the results substantially. At the same time, misclas-
sification of exposure to prostate biopsy, and the inclusion of
men undergoing prostate biopsy in the background popula-
tion used to calculate expected numbers of events, is unlikely
to have had any appreciable impact because they represent
such a small proportion of the entire population of men in
Scotland. Of greater concern would be inaccurate coding of
prostate biopsy in our study population yielding events that
are not actually associated with a prior prostate biopsy. The
overwhelming majority (97%) of hospital records had a re-
cord of prostate biopsy within seven days of the corre-
sponding pathology record in our regional comparison, and
we were able to verify that all deaths within 30 days of
prostate biopsy (according to linked hospitalization and
mortality records), had indeed undergone prostate biopsy30 days before death. Against this background, we believe
that our main study findings probably provide a reasonably
accurate representation of the consequences of prostate bi-
opsy in Scotland.
Other strengths include the size of the study population,
which was derived from all public sector acute general hos-
pitals in Scotland. The quality of cancer registration data,
used to determine whether prostate cancer was diagnosed in
each member of the study cohort, is believed to be compar-
atively good in Scotland, based on routinely available in-
dicators,21 and specific studies of completeness of case
ascertainment22 and data reliability.23 A further strength was
the ability to standardize for socio-economic deprivation.
A potential weakness of our study has been the reliance on
clinical coding within hospital administrative data, not only
to identify patients undergoing prostate biopsy but also to
generate the Charlson index of (prior) co-morbidity and to
identify reasons for subsequent hospital admissions. How-
ever, in Scotland, general hospitalization data are supported
by an active programme of quality assurance including reg-
ular assessments of data quality.24 As discussed above, it
seems likely that prostate biopsy is usually coded correctly
when recorded, but is often missing from hospital records.
For all procedures and diagnoses, the overall accuracy of
coding of main operation/procedure and main diagnosis has
been estimated to be around 94% and 88%, respectively and
has remained relatively stable for at least 20 years.25 A further
limitation of our study was that we were not able to capture
p u b l i c h e a l t h 1 4 2 ( 2 0 1 7 ) 1 0 2e1 1 0108information on prostate biopsy-associated morbidity diag-
nosed and managed exclusively in hospital outpatient or
primary care settings.
Our categories of prior co-morbidity, which were specified
before analysis, resulted in very small numbers of cases in the
highest categories of co-morbidity. Consequently, there was
limited statistical power to detect excess risks of hospitaliza-
tion or death in these categories.
Although we restricted our study to the first biopsy per
patient, for the majority of the cohort (86%), this was their
only biopsy recorded during the study period. However, it is
important to acknowledge that we may not have identified
the first biopsy for every patient, if some had a previous bi-
opsy that was unrecorded in hospitalization data. Gallina
et al.6 found a higher risk of death for first ever compared
with subsequent prostate biopsies, and other studies have
found that repeat biopsy was not associated with a greater
risk of serious complications compared with initial
biopsy.13,26,27
Unfortunately, we did not have access to information on
the reason(s) for biopsy, so we were not able to investigate
whether, for example, men presenting with urinary symp-
toms were more likely to be hospitalized with urinary symp-
toms following their prostate biopsy.
In summary, we have shown increased risks of hospitali-
zation and death in a cohort of men undergoing prostate bi-
opsy. Although some events seem likely to be associated with
a subsequent diagnosis of prostate cancer, it is likely that
some are associated more directly or indirectly with prostate
biopsy. The higher relative risk of events in older patients and
patients with prior co-morbidity emphasizes the need for
careful patient selection and justifies ongoing efforts to
minimize the risk of complications.Author statements
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ICD-10
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I33.- Acute and subacute
K61.- Abscess of anal and
K62.8 Other specified disea
K65.- Peritonitis
N15.1 Renal and perinephr
N15.9 Renal tubulo-interst
N28.8 Other specified disor
N30.0 Acute cystitis
N30.3 Trigonitis (urethrotr
N30.8 Other cystitis (absce
N30.9 Cystitis, unspecified
N34.- Urethritis and ureth
N39.0 Urinary tract infectio
N41.- Inflammatory diseas
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N49.- Inflammatory disord
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sy of prostate (includes needle biopsy of prostate NEC and biopsy of
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ospital admission categories (See Table 2dbased on any mention)
agic anaemia
s and rectum
tent haematuria
orrhage of prostate
ria
aematoma complicating a procedure, not elsewhere classified
f unspecified site
endocarditis
rectal regions
ses of anus and rectum (including proctitis, NOS)
ic abscess
itial disease, unspecified (Infection of kidney, NOS)
ders of kidney and ureter (including pyelitis and pyeloureteritis)
igonitis)
ss of bladder)
ral syndrome
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Other procedure-related complications
ICD-10
T81.1 Shock during or resulting from a procedure, not elsewhere classified
T81.2 Accidental puncture and laceration during a procedure, not elsewhere classified
Other urinary symptoms
ICD-10
N39.3 Stress incontinence
N39.4 Other specified urinary incontinence
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T83.0 Mechanical complication of urinary (indwelling) catheter
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M47.- Urethral catheterization of bladder
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